Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.

Conclusions: miR-362-5p/Sema3A might provide a promising therapeutic pathway and represents a candidate therapeutic target of the TNBC subtype. PMID: 31929841 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31929841?dopt=Abstract

Source: Disease Markers - January 15, 2020 Category: Laboratory Medicine Tags: Dis Markers Source Type: research